Study to test success of vision loss drug which could slash treatment costs for NHS
Nottingham researchers are leading a study to test the effectiveness of a controversial drug in the treatment of a common loss of vision.
If proved successful in treating wet age-related macular degeneration (AMD), the use of the drug Bevacizumab commercially branded as Avastin® could reduce the dose and frequency of patients' treatment, while potentially slashing the cost of treating the disease for the NHS.
It could prove the case for replacing the drug Ranibuzumab (Lucentis®), which is currently recommended by the National Institute for Health and Clinical Excellence (NICE) for the treatment of wet AMD.
The four-year TANDEM study is being led by Mr Alexander Foss, an honorary special lecturer in the School of Biomedical Sciences at The University of Nottingham and Consultant Ophthalmologist at Nottingham University Hospitals NHS Trust.
Mr Foss said: "The currently available evidence all points to the fact that Bevacizumab is of similar effectiveness and safety to Ranibizumab at a fraction of the cost.
"What we really seek to test is whether a lower dose of Bevacizumab can be used in place of a higher dose and whether two-monthly rather than monthly review can maintain the same treatment results.
Bevacizumab works in a similar way to Ranibuzumab and, although it is currently only licensed for use in treating cancer, a handful of health trusts in the UK have agreed that is can be prescribed to treat wet AMD.
The move hit the headlines recently following the decision by pharmaceutical company Novartis maker of the drug Lucentis to challenge the decision by seeking a judicial review of the policy to pay for Avastin on the NHS.
However, at a time when the NHS has been told to find £20 billion in savings by 2015, more cost-effective alternatives for commonly used drugs are hugely attractive to cash-strapped local trusts.
Lucentis costs in the region of £740 per injection, while Avastin is a fraction of the cost at £60 per injection. The Nottingham research is aiming to establish whether it could reduce the financial burden on the NHS further by being offered in a smaller dose and at less regular intervals.
Giving the drug every two months would also be beneficial to the patients, many of whom are elderly, who need to travel to hospital for the treatment.
Wet AMD is a common eye condition among people aged 50 and older. Over time, the disease destroys the macula, the part of the eye that provides the sharp, central vision needed for seeing objects clearly, and is the leading cause of vision loss in older adults.
In wet AMD, abnormally high levels of vascular endothelial growth factor (VEGF) are secreted in the eye, promoting the growth of new abnormal blood vessels. The Lucentis and Avastin both work by blocking the effect of the VEGF.
The Nottingham researchers are currently seeking to recruit around 2,000 patients aged 50 plus, at a number of centres around the East Midlands, who have recently been referred for wet AMD and who have not received treatment to either eye for the condition during the previous six months.
Two major trials CATT and IVAN (which also involved researchers from The University of Nottingham) have reported showing that Avastin and Lucentis are of similar effectiveness. The TANDEM trial is designed to complement these existing trials and in particular to address the important issues of dose (given the safety concern raised with these agents) and frequency of dosing. The trial is designed as a two by two factorial study generating four equal sized groups. One factor is the dose, with half the patients receiving standard dose and the other half receiving a low dose equivalent to half the standard dose and the other factor being frequency, with half the patients being seen monthly and half bimonthly.
Theoretical calculations suggest that half the standard dose should be more than sufficient to generate a full clinical response with an anticipated improved safety profile (complications include such serious condition as strokes) and there is substantial circumstantial evidence that bimonthly, rather than monthly, dosing should prove sufficient to obtain the full clinical benefit.
Mr Greg Fell, Consultant in Public Health and Chairman of the TANDEM Steering Committee, said: "This is an important issue for the NHS, and one where the NHS should be very careful and methodical in how it proceeds. There are genuine unanswered scientific questions which this study will shed light on."
Provided by University of Nottingham
- Avastin and Lucentis are equivalent in treating age-related macular degeneration Apr 30, 2012 | not rated yet | 0
- Researchers find no difference in drugs for macular degeneration Oct 01, 2010 | not rated yet | 0
- Avastin has similar effect to Lucentis in treating wet age-related macular degeneration May 07, 2012 | not rated yet | 0
- Study finds Avastin and Lucentis are equally effective in treating AMD Apr 28, 2011 | not rated yet | 0
- Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration Oct 09, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Learning curve of Electromagnetism?
1 hour ago I'm taking a first year physics course and have been having a little trouble with the basics of newtons laws and forces and whatnot, though nothing...
thin glass in liquid
2 hours ago I have one question about optics because I start interested in it. If an object is placed a distance p from a thin glass lens (index of refraction...
How many joules expended for a push up?
5 hours ago Just wondering if any of you can do the calculation that well approximates the amount of joules expended by a push up.
force to keep the folding doors
5 hours ago Hello, I would like to ask you to calculate the force F, which needed to keep the folding doors in this position. I would like to know what is the...
Confusion regarding direction of kinetic friction on inclined plane.
6 hours ago *please help! * The formula for kinetic friction acting on a sliding body is μkN When the body is sliding with constant velocity down an...
12 hours ago Alright, so in Pathfinder (like Dungeons and Dragons) there's a spell that allows you to lift/move stuff within 25 ft with 5 pounds of force. A...
- More from Physics Forums - Classical Physics
More news stories
The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial ...
Ophthalmology May 17, 2013 | not rated yet | 0 |
New research is emphasizing the importance of regular screenings for glaucoma, a disease that deteriorates the optic nerve over time and is a leading cause of irreversible blindness worldwide. The onset of glaucoma is associated ...
Ophthalmology May 17, 2013 | not rated yet | 0 |
The University of Nottingham and Nottingham University Hospitals NHS Trust, have been working with Sony Computer Entertainment Europe (SCEE) to develop special 3-D glasses and games to help treat children ...
Ophthalmology May 08, 2013 | not rated yet | 0
The first successful cornea transplant with donor endothelial tissue preloaded by an eye bank has been performed at Massachusetts Eye and Ear in Boston, Mass. Roberto Pineda II, M.D., Director of the Refractive Surgery Service ...
Ophthalmology May 07, 2013 | 5 / 5 (1) | 0
Adding omega-3 fatty acids did not improve a combination of nutritional supplements commonly recommended for treating age-related macular degeneration (AMD), a major cause of vision loss among older Americans, ...
Ophthalmology May 06, 2013 | 3 / 5 (2) | 0 |
An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).
5 hours ago | not rated yet | 0 |
The latest makeover to a massive psychiatric tome honored by some, reviled by others and even called the "Bible" of mental disorders is being released Saturday with a host of new changes.
2 hours ago | not rated yet | 0
A new case of the deadly coronavirus has been detected in Saudi Arabia where 15 people have already died after contracting it, the health ministry announced on Saturday on its Internet website.
3 hours ago | not rated yet | 0
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
13 hours ago | 5 / 5 (1) | 0
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
14 hours ago | 5 / 5 (1) | 0 |
A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...
5 hours ago | 5 / 5 (1) | 0